In vitro drug combination of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil with anti-human immunodeficiency virus or anticancer nucleosides.
1-beta-D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and E-5-(2-bromovinyl)uracil, a metabolite of BV-araU, did not affect either the anti-human immunodeficiency virus activity or the cytotoxicity of azidothymidine in MT-4 and MOLT-4 cells. Similarly, the bromovinyl compounds did not affect the in vitro antitumor activities of arabinosylcytosine, 5-fluorouracil, and 5-fluoro-2'-deoxyuridine. The anti-varicella-zoster virus activity of BV-araU was not influenced by azidothymidine, 2',3'-didehydro-2',3'-dideoxythymidine, or arabinosylcytosine, whereas relatively high concentrations of fluorinated antitumor agents enhanced the anti-varicella-zoster virus activity.
Machida
H
H
Biology Laboratory, Yamasa Shoyu Co., Ltd., Choshi, Japan.
Ashida
N
N
Ikeda
T
T
Sakata
S
S
Baba
M
M
Shigeta
S
S
D000998:Antiviral Agents / Q000494:pharmacology*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000494:pharmacology; D001976:Bromouracil / Q000031:analogs & derivatives* / Q000494:pharmacology; D003561:Cytarabine / Q000494:pharmacology; D004338:Drug Combinations; D005467:Floxuridine / Q000494:pharmacology; D005472:Fluorouracil / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects*; D014645:Herpesvirus 3, Human / Q000187:drug effects; D006801:Humans; D015215:Zidovudine / Q000494:pharmacology
D000998:Antiviral Agents; D004338:Drug Combinations; D005467:Floxuridine; D003561:Cytarabine; D001086:Arabinofuranosyluracil; D015215:Zidovudine; D001976:Bromouracil; C046140:5-(2-bromovinyl)uracil; C031368:sorivudine; D005472:Fluorouracil